In the hunt for investment chances, many experienced investors look to the ideas of value investing. This method, made famous by people like Benjamin Graham and Warren Buffett, centers on finding companies whose share price is lower than their calculated real worth. The aim is to discover good businesses that the market has incorrectly priced for now, providing a possible "margin of safety" for the patient investor. One way to find these candidates is by searching for stocks that show good basic traits, like earnings and a strong balance sheet, while also being priced at a large markdown, as shown by valuation measures. This method tries to steer clear of "value traps" by making sure the low-priced stock is supported by a company with solid basics.
Collegium Pharmaceutical Inc (NASDAQ:COLL), a specialty pharmaceutical company that works on creating and selling pain management treatments, recently came up from such a search. The company was found using a "Decent Value" filter that looks for stocks with a high valuation score, meaning they are low-priced, while still having acceptable scores in growth, earnings, and balance sheet strength. A look at Collegium's fundamental analysis report gives a close view of why it might match this description.
Valuation: A Clear Case for Being Undervalued
The central idea of value investing is buying a dollar's worth of assets for fifty cents. Collegium's valuation numbers indicate the market may be giving such a low price. The company's ChartMill Valuation Rating is a high 8 out of 10, putting it with the more low-priced stocks in its field.
- Price-to-Earnings (P/E) Ratio: At 4.35, Collegium's P/E ratio is much lower than the field average of 55.35 and the S&P 500's average of 24.88. It is priced lower than 96% of its pharmaceutical industry peers.
- Forward P/E Ratio: The view stays similar looking forward, with a forward P/E of 4.26, which is lower than 95% of the industry.
- Enterprise Value to EBITDA & Price/Free Cash Flow: Other important valuation measures also point to a low price. The company's Enterprise Value to EBITDA and Price/Free Cash Flow ratios are lower than about 97% of its industry competitors.
For a value investor, these numbers are the first attraction. They imply the market has set a low cost on Collegium's earnings and cash flow, possibly making a chance if the company's main business stays strong.
Profitability: The Engine Behind the Value
A low-priced stock is only a good buy if the company can produce earnings. This is where Collegium's description becomes much stronger, helping to lower the danger of a value trap. The company has a ChartMill Profitability Rating of 8, pointing to good earnings ability.
- Return Metrics: Collegium's Return on Equity (ROE) of 20.84% and Return on Invested Capital (ROIC) of 10.19% are better than over 90% of its industry peers. These numbers show effective use of shareholder money.
- Healthy Margins: The company keeps an operating margin of 23.01%, better than almost 90% of the industry, and a good gross margin of 59.35%. Significantly, its operating margin has gotten better in recent years.
This high level of earnings is key for the value argument. It shows that Collegium is not just a weak company with a low share price, but a profitable business whose shares are priced at a large markdown to its earnings power.
Financial Health: Assessing the Balance Sheet
Balance sheet strength is an important filter for value investors, as too much debt can harm a company, more so in hard economic times. Collegium's Health Rating is a middle 5, giving a varied view that needs close thought.
- Positive Aspects: The company's Debt-to-Free Cash Flow ratio is a very good 2.47, meaning it could pay off all its debt with less than two and a half years of cash flow. This ratio is better than 93% of the industry and suggests the debt load is workable compared to cash creation.
- Areas of Concern: But, the company has a high Debt-to-Equity ratio of 2.59 and has an Altman-Z score in the "distress zone," which marks possible bankruptcy risk. Its liquidity ratios (Current and Quick Ratio) are also under industry averages.
While the high earnings and good free cash flow give some protection, the raised debt amounts are a clear risk. A value investor would need to balance this against the company's cash-making ability and the large valuation markdown.
Growth: The Past vs. The Future
Growth gives the push that can narrow the space between market price and real value. Collegium's Growth Rating is a 6, showing a good past record but quiet future outlooks.
- Strong Past Performance: Over the last year and on a multi-year average, Collegium has shown very good growth in both Revenue (over 20% each year) and Earnings Per Share (almost 58% on average).
- Slowing Future Expectations: Analysts predict a slowdown, with EPS expected to fall a little over the next years and revenue growth settling to a low single-digit rate.
This situation is usual for value stocks. The market often prices in a time of slower growth or settling. The investment idea depends on whether the company can steady and keep its high earnings, letting the low valuation adjust as the market sees the continued earnings power.
Conclusion and Further Research
Collegium Pharmaceutical gives a strong case for investors using a value-focused filter. It trades at a large markdown to the market and its industry based on normal earnings measures, yet it is supported by a business that currently makes high returns on capital and good operating margins. This mix of low price and high earnings matches the value investing aim of finding quality at a discount.
But, the review is not simple. The company's balance sheet strength, especially its debt amounts, brings in risk that must be seen. Also, the expected slowdown in growth needs investors to believe in the company's long-term steadiness in the pain management market.
For investors wanting to look for similar chances, the "Decent Value" filter that found Collegium can be a helpful beginning. You can find more stocks that fit these needs of good valuation along with acceptable basics by viewing the filter results here.
Disclaimer: This article is for information only and is not financial advice, a suggestion, or an offer to buy or sell any security. The review is based on given data and shows the author's understanding. Investing has risk, including the chance of losing the original investment. You should do your own full research and think about talking with a qualified financial advisor before making any investment choices.